KR100776093B1 - 비-뉴클레오사이드 역전사효소 억제제 - Google Patents

비-뉴클레오사이드 역전사효소 억제제 Download PDF

Info

Publication number
KR100776093B1
KR100776093B1 KR1020057015085A KR20057015085A KR100776093B1 KR 100776093 B1 KR100776093 B1 KR 100776093B1 KR 1020057015085 A KR1020057015085 A KR 1020057015085A KR 20057015085 A KR20057015085 A KR 20057015085A KR 100776093 B1 KR100776093 B1 KR 100776093B1
Authority
KR
South Korea
Prior art keywords
alkyl
alkoxy
group
substituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057015085A
Other languages
English (en)
Korean (ko)
Other versions
KR20050105471A (ko
Inventor
제임스 패트릭 둔
조안 헤더 호그
타라네 미르자데간
스티븐 스왈로우
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20050105471A publication Critical patent/KR20050105471A/ko
Application granted granted Critical
Publication of KR100776093B1 publication Critical patent/KR100776093B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057015085A 2003-02-18 2004-02-17 비-뉴클레오사이드 역전사효소 억제제 Expired - Fee Related KR100776093B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44797403P 2003-02-18 2003-02-18
US60/447,974 2003-02-18

Publications (2)

Publication Number Publication Date
KR20050105471A KR20050105471A (ko) 2005-11-04
KR100776093B1 true KR100776093B1 (ko) 2007-11-15

Family

ID=32908518

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057015085A Expired - Fee Related KR100776093B1 (ko) 2003-02-18 2004-02-17 비-뉴클레오사이드 역전사효소 억제제

Country Status (17)

Country Link
US (1) US7241794B2 (enExample)
EP (1) EP1597235B1 (enExample)
JP (1) JP4608480B2 (enExample)
KR (1) KR100776093B1 (enExample)
CN (1) CN100389109C (enExample)
AR (1) AR043195A1 (enExample)
AT (1) ATE370124T1 (enExample)
BR (1) BRPI0407591A (enExample)
CA (1) CA2515151C (enExample)
CL (1) CL2004000270A1 (enExample)
DE (1) DE602004008227T2 (enExample)
ES (1) ES2291854T3 (enExample)
MX (1) MXPA05008748A (enExample)
PL (1) PL378556A1 (enExample)
RU (1) RU2305680C2 (enExample)
TW (1) TW200423930A (enExample)
WO (1) WO2004074257A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
JP4993407B2 (ja) 2004-08-04 2012-08-08 大正製薬株式会社 トリアゾール誘導体
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
PL1988083T3 (pl) 2006-02-03 2014-08-29 Taisho Pharmaceutical Co Ltd Pochodna triazolowa
RU2395499C2 (ru) 2006-02-06 2010-07-27 Тайсо Фармасьютикал Ко., Лтд. Ингибитор связывания сфингозин-1-фосфата
KR101401139B1 (ko) * 2006-02-14 2014-05-29 이하라케미칼 고교가부시키가이샤 5-알콕시-4-히드록시메틸피라졸 화합물의 제조방법
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
DE602007013573D1 (de) * 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
MX2009009920A (es) 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
ATE554070T1 (de) 2007-08-01 2012-05-15 Taisho Pharmaceutical Co Ltd Hemmer der s1p1-bindung
AU2008340422B2 (en) * 2007-12-21 2014-06-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
ES2565193T3 (es) 2010-07-15 2016-04-01 Sumitomo Dainippon Pharma Co., Ltd. Compuesto de pirazol
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2876969A1 (en) 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
BR112014031896A2 (pt) 2012-06-20 2017-06-27 Univ Vanderbilt composto, composição farmacêutica, e, método para o tratamento de um distúrbio
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en) 2013-09-06 2016-03-03 Inception 2, Inc. Triazolone compounds and uses thereof
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
US20180042234A1 (en) * 2015-03-19 2018-02-15 E I Du Pont De Nemours And Company Fungicidal pyrazoles
US20200002283A1 (en) * 2016-06-29 2020-01-02 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain
CN110818636A (zh) * 2019-11-29 2020-02-21 河北科技大学 一种化合物或其盐及其应用和合成方法
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030907A1 (en) * 2000-10-10 2002-04-18 F. Hoffmann-La Roche Ag Pyrazole derivatives for the treatment of viral diseases
WO2002100853A1 (en) * 2001-06-04 2002-12-19 F. Hoffmann-La Roche Ag Pyrazole derivatives as hiv reverse transcriptase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509024A (pt) 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
DE19734664A1 (de) * 1997-08-11 1999-02-18 Bayer Ag (Hetero)Aryloxypyrazole
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0028484D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
SI1762567T1 (sl) * 2001-04-10 2012-08-31 Pfizer Derivati pirazola za zdravljenje HIV-a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030907A1 (en) * 2000-10-10 2002-04-18 F. Hoffmann-La Roche Ag Pyrazole derivatives for the treatment of viral diseases
WO2002100853A1 (en) * 2001-06-04 2002-12-19 F. Hoffmann-La Roche Ag Pyrazole derivatives as hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
CL2004000270A1 (es) 2005-02-04
US20040192666A1 (en) 2004-09-30
JP4608480B2 (ja) 2011-01-12
CA2515151C (en) 2010-11-30
DE602004008227D1 (de) 2007-09-27
US7241794B2 (en) 2007-07-10
RU2305680C2 (ru) 2007-09-10
AR043195A1 (es) 2005-07-20
DE602004008227T2 (de) 2008-05-15
EP1597235B1 (en) 2007-08-15
EP1597235A1 (en) 2005-11-23
RU2005128832A (ru) 2006-04-27
ATE370124T1 (de) 2007-09-15
MXPA05008748A (es) 2005-09-20
BRPI0407591A (pt) 2006-02-14
AU2004213134A1 (en) 2004-09-02
TW200423930A (en) 2004-11-16
ES2291854T3 (es) 2008-03-01
PL378556A1 (pl) 2006-05-02
JP2006515339A (ja) 2006-05-25
KR20050105471A (ko) 2005-11-04
WO2004074257A1 (en) 2004-09-02
CN1751028A (zh) 2006-03-22
CA2515151A1 (en) 2004-09-02
CN100389109C (zh) 2008-05-21

Similar Documents

Publication Publication Date Title
KR20050105471A (ko) 비-뉴클레오사이드 역전사효소 억제제
KR100413154B1 (ko) 4-(아릴아미노메틸렌)-2,4-디하이드로-3-피라졸론
TWI235752B (en) Inhibitors of c-JUN N-terminal kinases (JNK) and other protein kinases
JP4426660B2 (ja) ピラゾール誘導体、その製法および医薬としてのその使用
KR20070011475A (ko) Ｃｘｃｒ1 및 ｃｘｃｒ2 케모카인 길항제
US6538015B1 (en) Anti-HIV pyrazole derivatives
US7951956B2 (en) Benzoimidazole compound capable of inhibiting prostaglandin D synthetase
CA2983668A1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
AU2002325221A1 (en) Pyrazole Derivatives as HIV Reverse Transcriptase Inhibitors
KR20040103972A (ko) 신규 화합물
ES2298616T3 (es) Derivados de pirazol.
US9249148B2 (en) Tris(hetero)arylpyrazoles and use thereof
AU2004213134B2 (en) Non-nucleoside reverse transcriptase inhibitors
ES2305563T3 (es) Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih.
CN101775011B (zh) N-取代苯基-3-甲烯杂环芳烃-2,5-二甲基吡咯类化合物及其抗hiv/aids的应用
JPH0219111B2 (enExample)
CZ200212A3 (cs) Derivát benzoylpyridazinu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080415

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007760930000

Gazette reference publication date: 20071115

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101107

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101107

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000